EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy
AstraZeneca Reports Q1 Core EPS $2.49, Consensus $2.26
Correction to AstraZeneca Update
AstraZeneca to Keep 2025 Forecast If US Pharmaceutical Tariffs in Line With Other Sectors
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update
News Highlights: Top Company News of the Day - Tuesday at 5 AM ET
Earnings Scheduled For April 29, 2025
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update
Research Alert: Core Eps Beat Partly Helped By Tax Adjustment, Full Year Guidance Reiterated
FTSE 100 Today: Stocks Flat as HSBC, BP, AstraZeneca Post Results
AstraZeneca: Calquence-based Regimens For CLL Recommended For EU Approval; Discontinues Truqap Trial
AstraZeneca Q1 Results Climb, Maintains FY25 Outlook; Lifts Dividend
AstraZeneca Discontinues Phase 3 Prostrate Cancer Treatment Trial
AstraZeneca's Leukemia Treatment Regimen Recommended for EU Approval
Express News | AstraZeneca Reaffirms 2025 Guidance: Revenue Growth In High Single-Digit, Core EPS Growth In Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate
AstraZeneca Sales, Earnings Rise
AstraZeneca Q1 Adj. EPADS $1.25 Beats $1.11 Estimate, Sales $13.59B Miss $13.71B Estimate
AstraZeneca: Committed to Further Invest and Grow in the U.S.
AstraZeneca Backs 2025 View
AstraZeneca 1Q Revenue Consensus Was $13.80B